Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by The Multiple Sclerosis Genetics Group,
Right arrow Articles by Hauser, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by The Multiple Sclerosis Genetics Group,
Right arrow Articles by Hauser, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 125, No. 1, 150-158, January 1, 2002
© 2002 Oxford University Press

Genetic basis for clinical expression in multiple sclerosis

The Multiple Sclerosis Genetics Group, L. F. Barcellos1, J. R. Oksenberg1, A. J. Green1, P. Bucher1, J. B. Rimmler2, S. Schmidt2, M. E. Garcia3, R. R Lincoln1, M. A. Pericak-Vance2, J. L. Haines3 and S. L. Hauser1

1Department of Neurology, University of California, San Francisco, California, 2Center for Human Genetics, Department of Medicine, Duke University Medical Center, Durham, North Carolina, and 3Program in Human Genetics, Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, USA Correspondence to: S. L. Hauser, Department of Neurology, University of California at San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143-0114, USA E-mail: hauser{at}itsa.ucsf.edu

Multiple sclerosis is a clinically heterogeneous demyelinating disease and an important cause of acquired neurological disability. An underlying complex genetic susceptibility plays an important role in multiple sclerosis aetiology; however, the role of genetic factors in determining clinical features of multiple sclerosis is unknown. We studied 184 stringently ascertained Caucasian multiple sclerosis families with multiple affected cases. A detailed evaluation of patient histories identified clinical variables including age of onset, initial clinical manifestations and disease severity. The concordance within families for continuous and categorical clinical variables was investigated using an intraclass correlation or Cohen’s kappa coefficient, respectively. Genetic analyses included model-dependent, model-independent and association methodology. Linear and logistic regression models were used to evaluate the effect of human leucocyte antigen (HLA)-DR2 (DRB1*1501, DQB1*0602) on clinical outcome, taking account of correlation within families. Significant concordance for early clinical manifestations within families was observed for individuals with exclusive optic neuritis and/or spinal cord involvement as first and second multiple sclerosis attacks (P < 10–6). Linkage (LOD = 3.80, {theta} = 0.20) and association (P = 0.0002) to HLA-DR were present in the dataset; however, linkage was restricted to families in which the DR2 haplotype was present in at least one nuclear member. No evidence for linkage to HLA-DR in DR2-negative families was observed. When families were stratified by concordance of early clinical manifestations, a significant DR2 association was present in all subgroups. Concordance for early manifestations of multiple sclerosis was present in this familial dataset, but was not associated with HLA-DR2. The association of DR2 in families with different clinical presentations suggests that a common basis exists for susceptibility in multiple sclerosis. However, non-HLA genes or other epigenetic factors must modulate disease expression. Locus heterogeneity at the HLA region suggests a distinct immunopathogenesis in DR2 negative patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
E M Mowry, S Deen, I Malikova, J Pelletier, P Bacchetti, and E Waubant
The onset location of multiple sclerosis predicts the location of subsequent relapses
J. Neurol. Neurosurg. Psychiatry, April 1, 2009; 80(4): 400 - 403.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
S. E. Baranzini, J. Wang, R. A. Gibson, N. Galwey, Y. Naegelin, F. Barkhof, E.-W. Radue, R. L.P. Lindberg, B. M.G. Uitdehaag, M. R. Johnson, et al.
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis
Hum. Mol. Genet., February 15, 2009; 18(4): 767 - 778.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
B. A. C. Cree, D. E. Reich, O. Khan, P. L. De Jager, I. Nakashima, T. Takahashi, A. Bar-Or, C. Tong, S. L. Hauser, and J. R. Oksenberg
Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA
Arch Neurol, February 1, 2009; 66(2): 226 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
O. Stuve, C. Korth, P. Gabatto, E. M. Cameron, W. Hu, T. N. Eagar, N. L. Monson, E. M. Frohman, M. K. Racke, C. P. Zabetian, et al.
Genetic Polymorphism at Codon 129 of the Prion Protein Gene Is Not Associated With Multiple Sclerosis
Arch Neurol, February 1, 2009; 66(2): 280 - 281.
[Full Text] [PDF]

Home page
 BrainHome page
D. T. Okuda, R. Srinivasan, J. R. Oksenberg, D. S. Goodin, S. E. Baranzini, A. Beheshtian, E. Waubant, S. S. Zamvil, D. Leppert, P. Qualley, et al.
Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures
Brain, January 1, 2009; 132(1): 250 - 259.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
S Deen, P Bacchetti, A High, and E Waubant
Predictors of the location of multiple sclerosis relapse
J. Neurol. Neurosurg. Psychiatry, October 1, 2008; 79(10): 1190 - 1193.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
H. Schmidt, D. Williamson, and A. Ashley-Koch
HLA-DR15 Haplotype and Multiple Sclerosis: A HuGE Review
Am. J. Epidemiol., May 15, 2007; 165(10): 1097 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. E. Hensiek, S. R. Seaman, L. F. Barcellos, A. Oturai, M. Eraksoi, E. Cocco, L. Vecsei, G. Stewart, B. Dubois, J. Bellman-Strobl, et al.
Familial effects on the clinical course of multiple sclerosis
Neurology, January 30, 2007; 68(5): 376 - 383.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
S Love
Demyelinating diseases.
J. Clin. Pathol., November 1, 2006; 59(11): 1151 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
L. F. Barcellos, S. Sawcer, P. P. Ramsay, S. E. Baranzini, G. Thomson, F. Briggs, B. C.A. Cree, A. B. Begovich, P. Villoslada, X. Montalban, et al.
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis
Hum. Mol. Genet., September 15, 2006; 15(18): 2813 - 2824.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. M. Burwick, P. P. Ramsay, J. L. Haines, S. L. Hauser, J. R. Oksenberg, M. A. Pericak-Vance, S. Schmidt, A. Compston, S. Sawcer, R. Cittadella, et al.
APOE epsilon variation in multiple sclerosis susceptibility and disease severity: Some answers
Neurology, May 9, 2006; 66(9): 1373 - 1383.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Alter, E. Kahana, N. Zilber, A. Miller, and for the Israeli MS Study Group
Multiple sclerosis frequency in Israel's diverse populations
Neurology, April 11, 2006; 66(7): 1061 - 1066.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
J. A. Traherne, L. F. Barcellos, S. J. Sawcer, A. Compston, P. P. Ramsay, S. L. Hauser, J. R. Oksenberg, and J. Trowsdale
Association of the truncating splice site mutation in BTNL2 with multiple sclerosis is secondary to HLA-DRB1*15
Hum. Mol. Genet., January 1, 2006; 15(1): 155 - 161.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
E. M. Frohman, M. Filippi, O. Stuve, S. G. Waxman, J. Corboy, J. T. Phillips, C. Lucchinetti, J. Wilken, N. Karandikar, B. Hemmer, et al.
Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions
Arch Neurol, September 1, 2005; 62(9): 1345 - 1356.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B. A.C. Cree, O. Khan, D. Bourdette, D. S. Goodin, J. A. Cohen, R. A. Marrie, D. Glidden, B. Weinstock-Guttman, D. Reich, N. Patterson, et al.
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis
Neurology, December 14, 2004; 63(11): 2039 - 2045.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
A. Kheradvar, A. R. Tabassi, B. Nikbin, F. Khosravi, M. Naroueynejad, B. Moradi, and A. A. Amirzargar
Influence of HLA on progression of optic neuritis to multiple sclerosis: results of a four-year follow-up study
Multiple Sclerosis, October 1, 2004; 10(5): 526 - 531.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
N. K. U. Koehler, C. P. Genain, B. Giesser, and S. L. Hauser
The Human T Cell Response to Myelin Oligodendrocyte Glycoprotein: A Multiple Sclerosis Family-Based Study
J. Immunol., June 1, 2002; 168(11): 5920 - 5927.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.